LifeMD (NASDAQ:LFMD), a leader in virtual primary care, announced on April 10, 2026, the addition of Eli Lilly’s newly approved oral weight-loss medication, Foundayo (orforglipron), to its comprehensive weight management program.
The integration, powered by LillyDirect, allows eligible patients to access the first non-peptide, once-daily oral GLP-1 receptor agonist directly through the LifeMD platform.
The U.S. Food and Drug Administration (FDA) approved Foundayo on April 1, 2026, for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition.
Unlike injectable GLP-1 therapies, Foundayo is a small-molecule pill that can be taken at any time of day without specific food or water restrictions, addressing a major barrier to adherence for many patients.
Through LifeMD’s integration with LillyDirect, prescriptions can be fulfilled and shipped directly to patients' homes, streamlining the transition from virtual consultation to treatment.
LifeMD is offering Foundayo at a starting self-pay price of $149 per month for the initial dose.
Patients with eligible commercial insurance coverage may pay as little as $25 per month using a Lilly savings card.